Borden EC, Sen GC, Uze G, et al. Interferons at age 50：past, current and future impact on biomedicine[J]. Nature Reviews Drug Discovery, 2007, 6（12）：975-990.
[2]
Pestka S. The interferons：50 years after their discovery, there is much more to learn[J]. Journal of Biological Chemistry, 2007, 282（28）：20047-20051.
[3]
O'' Brien TR. Interferon-alfa, interferon-lambda and hepatitis C[J]. Nat Genet, 2009, 41（10）：1048-1050.
[4]
Beilharz MW, Cummins JM, Bennett AL. Protection from lethal influenza virus challenge by oral type 1 interferon[J]. Biochemical and Biophysical Research Communications, 2007, 355（3）：740-744.
[5]
Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis：a retrospective monocentric study of 45 patients[J]. British Journal of Ophthalmology, 2007, 91（3）：335-339.
[6]
Chen X, Niyonsaba F, Ushio H, et al. Synergistic effect of antibacterial agents human β-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli[J]. Journal of Dermatological Science, 2005, 40（2）：123-132.
[7]
Mookherjee N, Lippert DND, Hamill P, et al. Intracellular receptor for human host defense peptide LL-37 in monocytes[J]. The Journal of Immunology, 2009, 183（4）：2688-2696.
[8]
Kai-Larsen Y, Agerberth B. The role of the multifunctional peptide LL-37 in host defense[J]. Frontiers in Bioscience：A Journal and Virtual Library, 2007, 13：3760-3767.
[9]
Jacobsen F, Mittler D, Hirsch T, et al. Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections[J]. Gene Therapy, 2005, 12（20）：1494-1502.
Dannehl C, Gutsmann T, Brezesinski G. Surface activity and structures of two fragments of the human antimicrobial LL-37[J]. Colloids and Surfaces B：Biointerfaces, 2013, 109：129-135.
[14]
Shen J, Lu X, Jin X, et al. Expression of a novel dual-functional protein-The antimicrobial peptide LL-37 fused with human acidic fibroblast growth factor in Escherichia coli[J]. Protein Expression and Purification, 2012, 81（1）：119-125.
[15]
Charoenrat T, Khumruaengsri N, Promdonkoy P, et al. Improvement of recombinant endoglucanase produced in Pichia pastoris KM71 through the use of synthetic medium for inoculum and pH control of proteolysis[J]. Journal of Bioscience and Bioengineering, 2013, 116（2）：193-198.
[16]
Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37：an antimicrobial peptide with a role in inflammatory skin disease[J]. Annals of Dermatology, 2012, 24（2）：126-135.
[17]
Potvin G, Ahmad A, Zhang Z. Bioprocess engineering aspects of heterologous protein production in Pichia pastoris：A review[J]. Biochemical Engineering Journal, 2012, 64：91-105.
[18]
Lo TM, Teo WS, Ling H, et al. Microbial engineering strategies to improve cell viability for biochemical production[J]. Biotechnology Advances, 2013, 31（6）：903-914.
